Her primary areas of investigation include Internal medicine, Pharmacology, Pharmacokinetics, Gastroenterology and Pembrolizumab. Her Internal medicine research incorporates elements of Surgery, Melanoma, Oncology and Monoclonal. She combines subjects such as Protein kinase B, Chemotherapy, Toxicity, Nausea and MK-2206 with her study of Pharmacology.
Her Pharmacokinetics research is multidisciplinary, incorporating elements of Tolerability and Immunology. Her work investigates the relationship between Gastroenterology and topics such as Neutropenia that intersect with problems in Taxane and Cabazitaxel. In her study, Carcinoma is inextricably linked to Lung cancer, which falls within the broad field of Pembrolizumab.
Her primary areas of study are Internal medicine, Pharmacology, Pharmacokinetics, Oncology and In patient. Her Internal medicine research is multidisciplinary, relying on both Gastroenterology and Surgery. The various areas that Amita Patnaik examines in her Pharmacology study include Neutropenia, Monoclonal antibody, Docetaxel and Dose escalation.
The Pharmacokinetics study combines topics in areas such as Nausea, Tolerability and Toxicity. Her studies deal with areas such as Clinical trial, Cohort, Pathology, Chemotherapy and Carboplatin as well as Oncology. Her research in Pembrolizumab tackles topics such as Melanoma which are related to areas like Ipilimumab.
Internal medicine, Oncology, Cancer research, Cancer and In patient are her primary areas of study. Her research related to Adverse effect, Pembrolizumab, Pharmacokinetics, Tolerability and Nausea might be considered part of Internal medicine. Her studies in Adverse effect integrate themes in fields like Gastroenterology, MEK inhibitor, Pneumonitis, Toxicity and Rash.
The study incorporates disciplines such as Carboplatin, Pemetrexed, Overall survival, Lung cancer and Antitumor activity in addition to Pembrolizumab. Pharmacokinetics is a subfield of Pharmacology that she studies. Amita Patnaik has researched Oncology in several fields, including Clinical trial, Chemotherapy, Melanoma, Hazard ratio and Cohort.
Amita Patnaik spends much of her time researching Internal medicine, Oncology, Pembrolizumab, Adverse effect and Pharmacokinetics. Her Clinical trial, Nausea, Advanced melanoma and Discontinuation study are her primary interests in Internal medicine. Her research on Nausea also deals with topics like
Amita Patnaik has included themes like Cancer, Combination therapy and Hazard ratio in her Oncology study. Her research in Pembrolizumab intersects with topics in Carboplatin, Pemetrexed, Overall survival, Melanoma and Lung cancer. Her study focuses on the intersection of Pharmacokinetics and fields such as Toxicity with connections in the field of Colorectal cancer.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Pembrolizumab for the treatment of non-small cell lung cancer
Edward B. Garon;Naiyer A. Rizvi;Rina Hui;Natasha Leighl.
The New England Journal of Medicine (2015)
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Omid Hamid;Caroline Robert;Adil Daud;F. Stephen Hodi.
The New England Journal of Medicine (2013)
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial
Caroline Robert;Antoni Ribas;Jedd D. Wolchok;F. Stephen Hodi.
The Lancet (2014)
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma
Mark J. Ratain;Tim Eisen;Walter M. Stadler;Keith T. Flaherty.
Journal of Clinical Oncology (2006)
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study
Corey J Langer;Shirish M Gadgeel;Hossein Borghaei;Vassiliki A Papadimitrakopoulou.
Lancet Oncology (2016)
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
Antoni Ribas;Omid Hamid;Adil Daud;F. Stephen Hodi.
First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors
Timothy A. Yap;Li Yan;Amita Patnaik;Ivy Fearen.
Journal of Clinical Oncology (2011)
Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab
F. Stephen Hodi;Wen Jen Hwu;Richard Kefford;Jeffrey S. Weber.
Journal of Clinical Oncology (2016)
Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
Amita Patnaik;S. Peter Kang;Drew Rasco;Kyriakos P. Papadopoulos.
Clinical Cancer Research (2015)
The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer
Toshio Shimizu;Anthony W. Tolcher;Kyriakos P. Papadopoulos;Muralidhar Beeram.
Clinical Cancer Research (2012)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: